Page last updated: 2024-12-05

3-toluidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-toluidine: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID7934
CHEMBL ID3182179
SCHEMBL ID11789
MeSH IDM0093696

Synonyms (77)

Synonym
m-tolyl-amine
3-toluidine
3-aminophenylmethane
3-aminotoluene
108-44-1
aniline, 3-methyl-
m-toluidine
m-methylbenzenamine
3-methylbenzenamine
1-amino-3-methylbenzene
3-methylaniline
3-amino-1-methylbenzene
nsc-15349
nsc15349
wln: zr c1
benzenamine, 3-methyl-
3-aminotoluen
m-tolylamine
m-aminotoluene
m-toluidin
m-methylaniline
inchi=1/c7h9n/c1-6-3-2-4-7(8)5-6/h2-5h,8h2,1h
m-toluidine, 99%
ccris 4325
hsdb 2043
3-aminotoluen [czech]
ai3-19859
m-toluidin [czech]
nsc 15349
einecs 203-583-1
brn 0635944
m-toluidyna [polish]
STK387127
T0298
AKOS000119100
NCGC00091601-02
NCGC00091601-03
cas-108-44-1
dtxsid1026792 ,
dtxcid506792
NCGC00258817-01
tox21_201265
tox21_300568
NCGC00254415-01
meta-toluidine
m-toluidine, liquid or solid [un1708] [poison]
ec 203-583-1
m-toluidine, liquid or solid
m-toluidyna
unii-006fkq96t3
4-12-00-01813 (beilstein handbook reference)
006fkq96t3 ,
3-methylphenylamine
FT-0616412
m-toluidine [mi]
(m-methylphenyl)amine
3-aminotoluene [hsdb]
SCHEMBL11789
3-methyl-phenylamine
3-methyl-aniline
3-methyl aniline
meta-methylaniline
metatoluidine
3-methyl-benzamine
W-108717
PS-9299
CHEMBL3182179
F2190-0419
mfcd00007808
m-toluidine, analytical standard
m-toluidine 100 microg/ml in cyclohexane
Z57127904
phenmedipham tp3
BCP15285
Q1880736
3-(methyl)aniline
EN300-18342
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency48.85420.003041.611522,387.1992AID1159552; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency24.48510.001530.607315,848.9004AID1259401
estrogen nuclear receptor alphaHomo sapiens (human)Potency62.05230.000229.305416,493.5996AID743069
activating transcription factor 6Homo sapiens (human)Potency12.29980.143427.612159.8106AID1159516
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (28.57)18.7374
1990's0 (0.00)18.2507
2000's5 (35.71)29.6817
2010's3 (21.43)24.3611
2020's2 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.02

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.02 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index17.79 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.02)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]